Abstract
This chapter will focus on the pharmacologic treatment of adolescents (12–18 years) and adults with autism spectrum disorders (ASDs). Research on the pharmacotherapy of associated symptoms of autism, such as interfering repetitive behaviors, irritability (tantrums, aggression, self-injury), and hyperactivity will be reviewed. In addition, the available literature on drug treatment of psychiatric comorbidities in ASDs will be covered, including mood and anxiety disorders, among others. This chapter will cover the available literature in adolescents and adults with ASDs. Because research to date in ASDs has largely focused on the treatment of children, key double-blind, placebo-controlled studies in this population will be summarized where applicable. Further, many studies of pharmacotherapy include children as well as adolescents and/or adults, making it difficult to generalize the results to any population.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abell, F., & Hare, D. J. (2005). An experimental investigation of the phenomenology of delusional beliefs in people with Asperger syndrome. Autism, 9(5), 515–531.
Anderson, G. M., Freedman, D. X., Cohen, D. J., Volkmar, F. R., Hoder, E. L., McPhedran, P., et al. (1987). Whole blood serotonin in autistic and normal subjects. Journal of Child Psychology and Psychiatry, 28(6), 885–900.
Arnold, L. E., Aman, M. G., Cook, A. M., Witwer, A. N., Hall, K. L., Thompson, S., et al. (2006). Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45(10), 1196–1205.
Arora, M., Praharaj, S. K., Sarkhel, S., & Sinha, V. K. (2011). Asperger disorder in adults. Southern Medical Journal, 104(4), 264–268.
Atlas, J. A., & Gerbino-Rosen, G. (1995). Differential diagnostics and treatment of an inpatient adolescent showing pervasive developmental disorder and mania. Psychological Reports, 77(1), 207–210.
Autism Speaks. (2009). Autism speaks announces results reported for the study of fluoxetine in autism (SOFIA): First industry-sponsored trial for the Autism Clinical Trials Network (ACTN) [press release]. New York. Retrieved February 18, 2009, from http://www.autismspeaks.org/about-us/press-releases/autism-speaks-announces-results-reported-study-fluoxetine-autism-sofia
Baron-Cohen, S., Scahill, V. L., Izaguirre, J., Hornsey, H., & Robertson, M. M. (1999). The prevalence of Gilles de la Tourette syndrome in children and adolescents with autism: A large scale study. Psychological Medicine, 29(5), 1151–1159.
Beherec, L., Lambrey, S., Quilici, G., Rosier, A., Falissard, B., & Guillin, O. (2011). Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. Journal of Clinical Psychopharmacology, 31(3), 341–344.
Belsito, K. M., Law, P. A., Kirk, K. S., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 31(2), 175–181.
Birmaher, B., Quintana, H., & Greenhill, L. L. (1988). Methylphenidate treatment of hyperactive autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 27(2), 248–251.
Brahm, N. C., Fast, G. A., & Brown, R. C. (2008). Buspirone for autistic disorder in a woman with an intellectual disability. Annals of Pharmacotherapy, 42(1), 131–137.
Brodkin, E. S., McDougle, C. J., Naylor, S. T., Cohen, D. J., & Price, L. H. (1997). Clomipramine in adults with pervasive developmental disorders: A prospective open-label investigation. Journal of Child and Adolescent Psychopharmacology, 7(2), 109–121.
Chen, N. C., Bedair, H. S., McKay, B., Bowers, M. B., Jr., & Mazure, C. (2001). Clozapine in the treatment of aggression in an adolescent with autistic disorder. Journal of Clinical Psychiatry, 62(6), 479–480.
Clarke, D. J., LittleJohns, C. S., Corbett, J. A., & Joseph, S. (1989). Pervasive developmental disorders and psychoses in adult life. British Journal of Psychiatry, 155, 692–699.
Cohen, S. A., Fitzgerald, B. J., Khan, S. R., & Khan, A. (2004). The effect of a switch to ziprasidone in an adult population with autistic disorder: Chart review of naturalistic, open-label treatment. Journal of Clinical Psychiatry, 65(1), 110–113.
Coskun, M., & Mukaddes, N. M. (2008). Mirtazapine treatment in a subject with autistic disorder and fetishism. Journal of Child and Adolescent Psychopharmacology, 18(2), 206–209.
Desousa, A. (2010). An open-label trial of risperidone and fluoxetine in children with autistic disorder. Indian Journal of Psychological Medicine, 32(1), 17–21.
Dhossche, D. M., Reti, I. M., Shettar, S. M., & Wachtel, L. E. (2010). Tics as signs of catatonia: Electroconvulsive therapy response in 2 men. The Journal of ECT, 26(4), 266–269.
Di Martino, A., Melis, G., Cianchetti, C., & Zuddas, A. (2004). Methylphenidate for pervasive developmental disorders: Safety and efficacy of acute single dose test and ongoing therapy: An open-pilot study. Journal of Child and Adolescent Psychopharmacology, 14(2), 207–218.
Dossetor, D. R. (2007). ‘All that glitters is not gold’: Misdiagnosis of psychosis in pervasive developmental disorders—A case series. Clinical Child Psychology and Psychiatry, 12(4), 537–548.
Duggal, H. S. (2007). Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder. Journal of Child and Adolescent Psychopharmacology, 17(2), 261–263.
Fankhauser, M. P., Karumanchi, V. C., German, M. L., Yates, A., & Karumanchi, S. D. (1992). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry, 53(3), 77–82.
Fatemi, S. H., Realmuto, G. M., Khan, L., & Thuras, P. (1998). Fluoxetine in treatment of adolescent patients with autism: A longitudinal open trial. Journal of Autism and Developmental Disorders, 28(4), 303–307.
Findling, R. L., McNamara, N. K., Gracious, B. L., O’Riordan, M. A., Reed, M. D., Demeter, C., et al. (2004). Quetiapine in nine youths with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 14(2), 287–294.
Fisman, S., Steele, M., Short, J., Byrne, T., & Lavallee, C. (1996). Case study: Anorexia nervosa and autistic disorder in an adolescent girl. Journal of the American Academy of Child and Adolescent Psychiatry, 35(7), 937–940.
Fontenelle, L. F., Mendlowicz, M. V., Bezerra de Menezes, G., dos Santos Martins, R. R., & Versiani, M. (2004). Asperger syndrome, obsessive-compulsive disorder, and major depression in a patient with 45, X/46, XY mosaicism. Psychopathology, 37(3), 105–109.
Ghaziuddin, M., Ghaziuddin, N., & Greden, J. (2002). Depression in persons with autism: Implications for research and clinical care. Journal of Autism and Developmental Disorders, 32(4), 299–306.
Ghaziuddin, M., & Greden, J. (1998). Depression in children with autism/pervasive developmental disorders: A case-control family history study. Journal of Autism and Developmental Disorders, 28(2), 111–115.
Ghaziuddin, M., Tsai, L., & Ghaziuddin, N. (1991). Fluoxetine in autism with depression. Journal of the American Academy of Child and Adolescent Psychiatry, 30(3), 508–509.
Ghuman, J. K., Aman, M. G., Lecavalier, L., Riddle, M. A., Gelenberg, A., Wright, R., et al. (2009). Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. Journal of Child and Adolescent Psychopharmacology, 19(4), 329–339.
Gillott, A., & Standen, P. J. (2007). Levels of anxiety and sources of stress in adults with autism. Journal of Intellectual Disabilities, 11(4), 359–370.
Gobbi, G., & Pulvirenti, L. (2001). Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. Journal of Psychiatry and Neuroscience, 26(4), 340–341.
Golubchik, P., Sever, J., & Weizman, A. (2011). Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: Open-label trial. Clinical Neuropharmacology, 34(6), 216–219.
Gordon, C. T., State, R. C., Nelson, J. E., Hamburger, S. D., & Rapoport, J. L. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50(6), 441–447.
Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30(3), 245–255.
Handen, B. L., Sahl, R., & Hardan, A. Y. (2008). Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental and Behavioral Pediatrics, 29(4), 303–308.
Hardan, A. Y., Jou, R. J., & Handen, B. L. (2004). A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 14(3), 426–432.
Harvey, R. J., & Cooray, S. E. (1995). The effective treatment of severe repetitive behaviour with fluvoxamine in a 20 year old autistic female. International Clinical Psychopharmacology, 10(3), 201–203.
Hellings, J. A., Kelley, L. A., Gabrielli, W. F., Kilgore, E., & Shah, P. (1996). Sertraline response in adults with mental retardation and autistic disorder. Journal of Clinical Psychiatry, 57(8), 333–336.
Hellings, J. A., Weckbaugh, M., Nickel, E. J., Cain, S. E., Zarcone, J. R., Reese, R. M., et al. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15(4), 682–692.
Hellings, J. A., Zarcone, J. R., Crandall, K., Wallace, D., & Schroeder, S. R. (2001). Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology, 11(3), 229–238.
Hellings, J. A., Zarcone, J. R., Reese, R. M., Valdovinos, M. G., Marquis, J. G., Fleming, K. K., et al. (2006). A crossover study of risperidone in children, adolescents and adults with mental retardation. Journal of Autism and Developmental Disorders, 36(3), 401–411.
Hillbrand, M., & Scott, K. (1995). The use of buspirone with aggressive behavior. Journal of Autism and Developmental Disorders, 25(6), 663–664.
Hofvander, B., Delorme, R., Chaste, P., Nyden, A., Wentz, E., Stahlberg, O., et al. (2009). Psychiatric and psychosocial problems in adults with normal-intelligence autism spectrum disorders. BMC Psychiatry, 9, 35.
Hollander, E., Chaplin, W., Soorya, L., Wasserman, S., Novotny, S., Rusoff, J., et al. (2010). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 35(4), 990–998.
Hollander, E., Dolgoff-Kaspar, R., Cartwright, C., Rawitt, R., & Novotny, S. (2001). An open trial of divalproex sodium in autism spectrum disorders. Journal of Clinical Psychiatry, 62(7), 530–534.
Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., et al. (2012). A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry, 169(3), 292–299.
Horrigan, J. P., & Barnhill, L. J. (1997). Risperidone and explosive aggressive autism. Journal of Autism and Developmental Disorders, 27(3), 313–323.
Howell, P. C., Larson, J., & Coffey, D. B. (2011). Treatment of bipolar disorder in an adolescent with autistic disorder: A diagnostic and treatment dilemma. Journal of Child and Adolescent Psychopharmacology, 21(3), 283–286.
Jahromi, L. B., Kasari, C. L., McCracken, J. T., Lee, L. S., Aman, M. G., McDougle, C. J., et al. (2009). Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Journal of Autism and Developmental Disorders, 39(3), 395–404.
Jaselskis, C. A., Cook, E. H., Jr., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12(5), 322–327.
Kerbeshian, J., Burd, L., Randall, T., Martsolf, J., & Jalal, S. (1990). Autism, profound mental retardation and atypical bipolar disorder in a 33-year-old female with a deletion of 15q12. Journal of Mental Deficiency Research, 34(Pt 2), 205–210.
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590.
Koshes, R. J. (1997). Use of fluoxetine for obsessive-compulsive behavior in adults with autism. American Journal of Psychiatry, 154(4), 578.
Koshes, R. J., & Rock, N. L. (1994). Use of clonidine for behavioral control in an adult patient with autism. American Journal of Psychiatry, 151(11), 1714.
Kurita, H. (1999). Brief report: Delusional disorder in a male adolescent with high-functioning PDDNOS. Journal of Autism and Developmental Disorders, 29(5), 419–423.
Lambrey, S., Falissard, B., Martin-Barrero, M., Bonnefoy, C., Quilici, G., Rosier, A., et al. (2010). Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 20(1), 79–80.
Leboyer, M., Philippe, A., Bouvard, M., Guilloud-Bataille, M., Bondoux, D., Tabuteau, F., et al. (1999). Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biological Psychiatry, 45(2), 158–163.
Lugnegard, T., Hallerback, M. U., & Gillberg, C. (2011). Psychiatric comorbidity in young adults with a clinical diagnosis of Asperger syndrome. Research in Developmental Disabilities, 32(5), 1910–1917.
Malone, R. P., Delaney, M. A., Hyman, S. B., & Cater, J. R. (2007). Ziprasidone in adolescents with autism: An open-label pilot study. Journal of Child and Adolescent Psychopharmacology, 17(6), 779–790.
Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119.
Marcus, R. N., Owen, R., Manos, G., Mankoski, R., Kamen, L., McQuade, R. D., et al. (2011). Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study. Journal of Clinical Psychiatry, 72(9), 1270–1276.
Martin, A., Koenig, K., Scahill, L., & Bregman, J. (1999). Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 9(2), 99–107.
McCormick, L. H. (1997). Treatment with buspirone in a patient with autism. Archives of Family Medicine, 6(4), 368–370.
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321.
McDougle, C. J., Brodkin, E. S., Naylor, S. T., Carlson, D. C., Cohen, D. J., & Price, L. H. (1998). Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation. Journal of Clinical Psychopharmacology, 18(1), 62–66.
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998). A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry, 55(7), 633–641.
McDougle, C. J., Kem, D. L., & Posey, D. J. (2002). Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 41(8), 921–927.
McDougle, C. J., Kresch, L. E., Goodman, W. K., Naylor, S. T., Volkmar, F. R., Cohen, D. J., et al. (1995). A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. American Journal of Psychiatry, 152(5), 772–777.
McDougle, C. J., Kresch, L. E., & Posey, D. J. (2000). Repetitive thoughts and behavior in pervasive developmental disorders: Treatment with serotonin reuptake inhibitors. Journal of Autism and Developmental Disorders, 30(5), 427–435.
McDougle, C. J., Naylor, S. T., Cohen, D. J., Volkmar, F. R., Heninger, G. R., & Price, L. H. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53(11), 1001–1008.
McDougle, C. J., Price, L. H., & Goodman, W. K. (1990). Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: A case report. Journal of Autism and Developmental Disorders, 20(4), 537–543.
McDougle, C. J., Price, L. H., Volkmar, F. R., Goodman, W. K., Ward-O’Brien, D., Nielsen, J., et al. (1992). Clomipramine in autism: Preliminary evidence of efficacy. Journal of the American Academy of Child and Adolescent Psychiatry, 31(4), 746–750.
McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry, 162(6), 1142–1148.
Mehlinger, R., Scheftner, W. A., & Poznanski, E. (1990). Fluoxetine and autism. Journal of the American Academy of Child and Adolescent Psychiatry, 29(6), 985.
Munesue, T., Ono, Y., Mutoh, K., Shimoda, K., Nakatani, H., & Kikuchi, M. (2008). High prevalence of bipolar disorder comorbidity in adolescents and young adults with high-functioning autism spectrum disorder: A preliminary study of 44 outpatients. Journal of Affective Disorders, 111(2–3), 170–175.
Nguyen, M., & Murphy, T. (2001). Mirtazapine for excessive masturbation in an adolescent with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 40(8), 868–869.
Nickels, K., Katusic, S. K., Colligan, R. C., Weaver, A. L., Voigt, R. G., & Barbaresi, W. J. (2008). Stimulant medication treatment of target behaviors in children with autism: A population-based study. Journal of Developmental and Behavioral Pediatrics, 29(2), 75–81.
Niederhofer, H., Damodharan, S. K., Joji, R., Corfield, A. (2006). Atomoxetine treating patients with autistic disorder. Autism, 10(6), 647–649.
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533–1540.
Pardini, M., Guida, S., & Gialloreti, L. E. (2010). Aripiprazole treatment for coprophagia in autistic disorder. The Journal of Neuropsychiatry and Clinical Neurosciences, 22(4), 451-s.e433–451.e433.
Perry, D. W., Marston, G. M., Hinder, S. A., Munden, A. C., & Roy, A. (2001). The phenomenology of depressive illness in people with a learning disability and autism. Autism, 5(3), 265–275.
Posey, D. J., Aman, M. G., McCracken, J. T., Scahill, L., Tierney, E., Arnold, L. E., et al. (2007). Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: An analysis of secondary measures. Biological Psychiatry, 61(4), 538–544.
Posey, D. J., Guenin, K. D., Kohn, A. E., Swiezy, N. B., & McDougle, C. J. (2001). A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 11(3), 267–277.
Posey, D. J., Wiegand, R. E., Wilkerson, J., Maynard, M., Stigler, K. A., & McDougle, C. J. (2006). Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 599–610.
Potenza, M. N., Holmes, J. P., Kanes, S. J., & McDougle, C. J. (1999). Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. Journal of Clinical Psychopharmacology, 19(1), 37–44.
Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., et al. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders, 25(3), 283–294.
Realmuto, G. M., & Main, B. (1982). Coincidence of Tourette’s disorder and infantile autism. Journal of Autism and Developmental Disorders, 12(4), 367–372.
Remington, G., Sloman, L., Konstantareas, M., Parker, K., & Gow, R. (2001). Clomipramine versus haloperidol in the treatment of autistic disorder: A double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology, 21(4), 440–444.
Research Units on Pediatric Psychopharmacology. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274.
Rezaei, V., Mohammadi, M. R., Ghanizadeh, A., Sahraian, A., Tabrizi, M., Rezazadeh, S. A., et al. (2010). Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 34(7), 1269–1272.
Ritvo, E. R., Yuwiler, A., Geller, E., Ornitz, E. M., Saeger, K., & Plotkin, S. (1970). Increased blood serotonin and platelets in early infantile autism. Archives of General Psychiatry, 23(6), 566–572.
Roy, M., Dillo, W., Bessling, S., Emrich, H. M., & Ohlmeier, M. D. (2009). Effective methylphenidate treatment of an adult Aspergers syndrome and a comorbid ADHD: A clinical investigation with fMRI. Journal of Attention Disorders, 12(4), 381–385.
Santosh, P. J., Baird, G., Pityaratstian, N., Tavare, E., & Gringras, P. (2006). Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: A retrospective and prospective effectiveness study. Child: Care, Health and Development, 32(5), 575–583.
Schain, R. J., & Freedman, D. X. (1961). Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. Journal of Pediatrics, 58, 315–320.
Schmidt, K. (1982). The effect of stimulant medication in childhood-onset pervasive developmental disorder—A case report. Journal of Developmental and Behavioral Pediatrics, 3(4), 244–246.
Shastri, M., Alla, L., & Sabaratnam, M. (2006). Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: A case series. Journal of Psychopharmacology, 20(6), 863–867.
Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634–e641.
Stahlberg, O., Soderstrom, H., Rastam, M., & Gillberg, C. (2004). Bipolar disorder, schizophrenia, and other psychotic disorders in adults with childhood onset AD/HD and/or autism spectrum disorders. Journal of Neural Transmission, 111(7), 891–902.
Steingard, R., & Biederman, J. (1987). Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 26(6), 932–935.
Stigler, K. A., Diener, J. T., Kohn, A. E., Li, L., Erickson, C. A., Posey, D. J., et al. (2009). Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger’s disorder: A 14-week, prospective, open-label study. Journal of Child and Adolescent Psychopharmacology, 19(3), 265–274.
Stigler, K. A., Erickson, C. A., Mullett, J. E., Posey, D. J., & McDougle, C. J. (2010). Paliperidone for irritability in autistic disorder. Journal of Child and Adolescent Psychopharmacology, 20(1), 75–78.
Stigler, K. A., Mullett, J. E., Erickson, C. A., Posey, D. J., & McDougle, C. J. (2012). Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology, 223(2), 237–245.
Strayhorn, J. M., Jr., Rapp, N., Donina, W., & Strain, P. S. (1988). Randomized trial of methylphenidate for an autistic child. Journal of the American Academy of Child and Adolescent Psychiatry, 27(2), 244–247.
Sugie, Y., Sugie, H., Fukuda, T., Ito, M., Sasada, Y., Nakabayashi, M., et al. (2005). Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. Journal of Autism and Developmental Disorders, 35(3), 377–385.
Szatmari, P., Archer, L., Fisman, S., Streiner, D. L., & Wilson, F. (1995). Asperger’s syndrome and autism: Differences in behavior, cognition, and adaptive functioning. Journal of the American Academy of Child and Adolescent Psychiatry, 34(12), 1662–1671.
Tantum, D. (1991). Asperger syndrome in adulthood. In U. Frith (Ed.), Autism and Asperger’s syndrome. Cambridge, England: Cambridge University Press.
Vitiello, B., & Jensen, P. S. (1995). Developmental perspectives in pediatric psychopharmacology. Psychopharmacology Bulletin, 31(1), 75–81.
Volkmar, F. R., Klin, A., Schultz, R. T., Rubin, E., & Bronen, R. (2000). Asperger’s disorder. The American Journal of Psychiatry, 157(2), 262–267.
Wachtel, L. E., Griffin, M., & Reti, I. M. (2010). Electroconvulsive therapy in a man with autism experiencing severe depression, catatonia, and self-injury. The Journal of ECT, 26(1), 70–73.
Wasserman, S., Iyengar, R., Chaplin, W. F., Watner, D., Waldoks, S. E., Anagnostou, E., et al. (2006). Levetiracetam versus placebo in childhood and adolescent autism: A double-blind placebo-controlled study. International Clinical Psychopharmacology, 21(6), 363–367.
Whitaker-Azmitia, P. M. (1993). The role of serotonin and serotonin receptors in development of the mammalian nervous system. In I. S. Zagon & P. J. McLaughlin (Eds.), Receptors in the developing nervous system, Vol. 2, Neurotransmitters (pp. 43–53). London: Chapman & Hall.
Willemsen-Swinkels, S. H., Buitelaar, J. K., Nijhof, G. J., & van England, H. (1995). Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Archives of General Psychiatry, 52(9), 766–773.
Wing, L. (1981). Asperger’s syndrome: A clinical account. Psychological Medicine, 11(1), 115–129.
Wink, L. K., Erickson, C. A., Stigler, K. A., McDougle, C. J. (2011). Riluzole in autistic disorder. Journal of Child and Adolescent Psychopharmacology, 21(4), 375–379.
Zingarelli, G., Ellman, G., Hom, A., Wymore, M., Heidorn, S., & Chicz-DeMet, A. (1992). Clinical effects of naltrexone on autistic behavior. American Journal of Mental Retardation, 97(1), 57–63.
Acknowledgments
This work was supported by a Daniel X. and Mary Freedman Fellowship in Academic Psychiatry and a Career Development Award (K23 MH 082119) from the National Institute of Mental Health (NIMH) (Dr. Stigler) and the Nancy Lurie Marks Family Foundation, Autism Speaks, and the NIMH (ROIMH077600, ROIMH083739) (Dr. McDougle).
Disclosure of conflict of interest: Drs. Doyle and McDougle have nothing to disclose. Dr. Stigler receives research support from Brisol-Myers Squibb Co., Curemark, Eli Lilly & Co., Forest Research Institute, Janssen, Novartis, and Seaside Therapeutics.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Doyle, C.A., McDougle, C.J., Stigler, K.A. (2014). Pharmacotherapy of Behavioral Symptoms and Psychiatric Comorbidities in Adolescents and Adults with Autism Spectrum Disorders. In: Volkmar, F., Reichow, B., McPartland, J. (eds) Adolescents and Adults with Autism Spectrum Disorders. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0506-5_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0506-5_9
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0505-8
Online ISBN: 978-1-4939-0506-5
eBook Packages: Behavioral ScienceBehavioral Science and Psychology (R0)